ClinicalTrials.gg
CompletedNCT07764926Updated Aug 14, 2026

Effects of MNRI Therapy on Fine Motor Skills in Children With Developmental Delays.

An interventional study of MNRI and Conventional Physiotherapy without MNRI in MNRI and Development Delay, sponsored by Riphah International University. Completed at 1 site in Pakistan. Open to participants aged 2 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
2 Years to 6 Years
Sex
All
01

Study summary

Developmental delay refers to a child's failure to achieve age-appropriate developmental milestones and may affect multiple developmental domains. MNRI (Masgutova Neurosensorimotor Reflex Integration) therapy is designed to improve sensory-motor integration, motor coordination, and cognitive function in children with neurodevelopmental disorders by integrating impaired reflex pathways. This randomized clinical trial will be conducted at Children Complex Hospital on 34 participants divided into experimental and control groups. The experimental group will receive MNRI therapy, while the control group will receive standard care. Reflex integration and upper limb fine motor skills will be assessed over six months, and data will be analyzed using IBM SPSS Statistics.

Read the detailed description

Delay in development is generally determined with a child does not attain developmental milestones as compared to peers from the same population. "Developmental delay" is a general descriptor of a broad phenotype that must then be specified by carefully determining one or more elements linked with the area of disrupted development. Developmental delay is not a diagnosis by itself rather a categorical, illustrative term used in the clinic. Further, the terms often used to specify a developmental delay may vary by country or area of practice. For example, the term "mental retardation is no longer in use with "learning disability" being used in the UK and Intellectual Disability being used in the US to define a group of individuals with a significant delay defined by "performance equal or greater than two standard deviations below the mean on age-appropriate standardized norm-referenced testing" (IQ or intelligent quotient testing). The MNRI (Masgutova Neurosensorimotor Reflex Integration) processes are designed for individuals with neuro-developmental disorders and aimed at the improvement of their sensory-motor integration, motor coordination, and cognitive development. The MNRI therapy program is based on the supposition that impaired reflex circuits can be reconstructed.

A randomized clinical trial will be conducted at Children Complex Hospital in Multan. Non probability convenience sampling technique will be applied on 34 patients who will be allocated through simple random sampling into group A \& group B to collect data. Group A will be given Masgutova Neurosensorimotor Reflex Integration therapy (MNRI) and group B will be a control group. The study will be completed within the time duration of six months .Primary Outcome measures of the research will be reflexes and fine motor skills of upper limbs. Data will be analyzed using SPSS software version 25. After assessing normality of data by Shapiro-wilk test, it will be decided either parametric or non-parametric test will be used within a group or between two groups.

02

Conditions studied

  • MNRI
  • Development Delay

Browse trials for

Keywords

  • Delayed Milestones, MNRI, Pediatrics,
03

In context

Learning Disabilities

270 studies on the registry are indexed under Learning Disabilities; 62 are open to participants now.

This study's enrollment of 34 is below the median of 60 across 181 interventional studies indexed under Learning Disabilities.

Browse Learning Disabilities studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,193 studies on the registry; 650 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children of 2-6 years of age presenting with development delay.
  • Severity of development delay in each domain will be labeled as mild, moderate and severe categories according to Denver Developmental Scale-II .
  • Children showing signs of unintegrated primitive reflexes (e.g., Moro, ATNR, STNR, TLR, etc.), which MNRI specifically targets.

Exclusion criteria

Exclusion Criteria:

  • History of orthopedic surgery within the last half a year
  • Any other neurological or musculoskeletal disorders that might hamper the study's results (e.g., traumatic brain disorders, muscular dystrophy, and epilepsy).
  • Patients with autism and non-cooperative for development assessment.
  • Children whose development level was above 8 years of age as Griffith scale measures development age only up to 8 years .
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    MNRI Group

    Masgutova Neurosensorimotor Reflex Integration (MNRI) therapy is a neurodevelopmental intervention designed to improve reflex integration, sensory-motor coordination, and fine motor functioning in children with developmental delays through structured reflex-based therapeutic exercises by using Reflex assessment scales Fine motor skill assessment of upper limbs Standardized developmental assessment tools/questionnaires Statistical analysis using IBM SPSS Statistics

    Other: MNRI

  • Other
    control group without MNRI training

    A standardized physical treatment regimen was provided (Stretching exercise, Strengthening exercise, and facilitation of developing motor milestones) for the body. Static stretches will be given. Strengthening exercises using resistance bands or light weights

    Other: Conventional Physiotherapy without MNRI

Interventions

  • OtherMNRI

    Participants will receive Masgutova Neurosensorimotor Reflex Integration (MNRI) therapy administered by trained physiotherapists for 45-60 minutes per session, 5 days per week, for 4 weeks. Sessions will begin with stretching and strengthening exercises, followed by reflex integration activities targeting Moro, ATNR, STNR, TLR, and Spinal Galant reflexes through exercises such as Starfish, Cat-Cow, Cross Crawl, rocking, crawling, and proprioceptive activities. Upper limb training will include hand and wrist activation, proprioceptive stimulation, gripping activities, forearm activation, and grasp pattern exercises to improve fine motor skills and reflex integration.

  • OtherConventional Physiotherapy without MNRI

    Participants will receive a standardized conventional physiotherapy program administered by trained physiotherapists. The program will include stretching exercises for the upper and lower limb muscles, including static stretching of tight muscle groups, strengthening exercises using resistance bands or age-appropriate light weights, facilitation and practice of age-appropriate developmental motor milestones such as rolling, sitting, crawling, standing, walking, balance, and transitional movements, as well as functional upper limb activities to improve reaching, grasping, and object manipulation. Gross motor training will be individualized according to each child's developmental level. The intervention will be provided for 45-60 minutes per session, 5 days per week for 4 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Sollerman Hand Function Test (SHFT) total score from baseline to 4 weeks

    Fine motor function will be assessed using the Sollerman Hand Function Test (SHFT), a standardized 20-task assessment of hand function during activities of daily living. The total SHFT score ranges from 0 to 80, with higher scores indicating better hand function and manual dexterity. The primary outcome will be the change in total SHFT score from baseline to the end of the 4-week intervention.

    Time frame: 4 weeks

Secondary outcomes

  1. Change in Reflex Assessment Scale (RAS) score from baseline to 4 weeks

    Primitive reflex integration will be evaluated using the Reflex Assessment Scale (RAS). The outcome will be the change in total RAS score from baseline to 4 weeks. Lower scores indicate greater reflex integration.

    Time frame: 4 weeks

  2. Change in Pediatric Evaluation of Disability Inventory (PEDI) total score from baseline to 4 weeks

    Functional performance and independence in activities of daily living will be assessed using the Pediatric Evaluation of Disability Inventory (PEDI). The outcome will be the change in total PEDI score from baseline to 4 weeks. Higher scores indicate better functional ability.

    Time frame: 4 weeks

  3. Change in Participation and Sensory Environment Questionnaire (PSEQ) total score from baseline to 4 weeks

    Participation and the impact of sensory environments will be assessed using the Participation and Sensory Environment Questionnaire (PSEQ). The outcome will be the change in total PSEQ score from baseline to 4 weeks. Lower scores indicate fewer sensory-related participation difficulties.

    Time frame: 4 weeks

07

Study locations

1 site
  • Imran Amjad
    Lahore, Punjab Province 5400, Pakistan
08

References and documents

Publications

  • Stivaros S, Garg S, Tziraki M, Cai Y, Thomas O, Mellor J, Morris AA, Jim C, Szumanska-Ryt K, Parkes LM, Haroon HA, Montaldi D, Webb N, Keane J, Castellanos FX, Silva AJ, Huson S, Williams S, Gareth Evans D, Emsley R, Green J; SANTA Consortium. Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA). Mol Autism. 2018 Feb 22;9:12. doi: 10.1186/s13229-018-0190-z. eCollection 2018. PubMed 29484149 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07764926
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
May 11, 2026
Primary completion
Jun 27, 2026
Completion
Jul 27, 2026
Last update
Aug 14, 2026

Study contacts

Sonia Babar, MS-PT
principal investigator · Riphah International University, Islamabad

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion